Illumina plans $100M in cost cuts for 2025 after China bans its sequencers, impacting about 7% of its $4.3 billion sales. The firm lowered its 2025 adjusted EPS guidance to $4.50, at the low end ...
This single test interrogates over 500 genes to profile a patient ... Early-Phase Drug Development at Sarah Cannon Research Institute. “Illumina’s newest distributable IVD kit for comprehensive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback